Completed PHASE1 INTERVENTIONAL 2-arm NCT02824666

Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242

Phase 1, Open-Label Positron Emission Tomography (PET) Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242 in Adult Male Healthy Subjects

Sponsor: Braeburn Pharmaceuticals

Conditions Schizophrenia

Interventions ATI-9242 [18F]Fallypride Imaging

Updated 7 times since 2017 Last updated: Jul 13, 2017 Started: Jun 20, 2016 Primary completion: Sep 6, 2016 Completion: Nov 8, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Schizophrenia, this trial is completed. The trial is conducted by Braeburn Pharmaceuticals and has accumulated 7 data snapshots since 2016. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Aug 2017 — Jun 2018 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed

▶ Show 2 earlier versions

Feb 2017 — Aug 2017 [monthly]

Active Not Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE1

First recorded

Jun 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Braeburn Pharmaceuticals

Data source: Braeburn Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Indianapolis, United States